Home > News > Midatech nanoparticles heading for the clinic in Q1 2008
May 14th, 2007
Midatech nanoparticles heading for the clinic in Q1 2008
Midatech, the UK group exploring the therapeutic and diagnostic applications of nanoparticles as drug delivery vehicles, scaffolds for synthetic vaccines or antibiotics and non-invasive imaging agents, aims to put its first product into clinical trials in the first quarter of 2008.
This will be multivalent antibiotics delivered on nanoparticles, said Midatech's Storme Thornicroft. The group's listed pipeline includes a project coded MTL 201 that involves antibiotics for the treatment of the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
Treatment of Cell Infection by Nanotechnology September 15th, 2014
Researchers Create World’s Largest DNA Origami September 11th, 2014
Iranian Scientists Discover Nanotechnology Method to Remove Limitations in Tumor Surgery September 11th, 2014
Iranian Nanotechnology Scientists Produce Polymeric Scaffolds for Tissue Engineering September 11th, 2014
Dolomite to launch Meros TCU-100 temperature controller at Lab-on-a-Chip & Microarray World Congress September 15th, 2014
Fonon at Cutting-Edge of 3D Military Printing: Live-Combat Scenarios Could See a Decisive Advantage with 3D Printing September 15th, 2014
Rice rolls 'neat' nanotube fibers: Rice University researchers' acid-free approach leads to strong conductive carbon threads September 15th, 2014
Simple, Cost-Effective Method Proposed for Synthesizing Zinc Oxide Nanopigments September 15th, 2014